News and Announcements
Dimerix Reports Successful Phase 2a Trial of DMX-200, with 36% reduction in proteinuria in patients with Diabetic Nephropathy
- Published December 14, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Phase 2a clinical trial for lead program DMX-200 was successfully completed.
- Data from this study met primary safety endpoint, with encouraging efficacy signals.
- Addition of Non-Executive Director Mr Hugh Alsop and Head of Drug Development Dr Robert Shepherd to the team.
- Share consolidation completed.
The successful completion of the Phase 2a clinical trial for our lead program, DMX-200, in Chronic Kidney Disease was the unequivocal highlight of the year. Not only did the data from this study meet the important primary endpoint of safety, the exciting and unexpected observation was that a statistically significant efficacy response was seen in the subgroup of patients with diabetic nephropathy. These clinical outcomes significantly enhance the underlying value proposition for DMX-200.
The year has also seen us bolster our team, complete a share consolidation and start marketing our trial data to pharmaceutical partners and investors on the world stage.
About Dimerix Limited (ASX: DXB)
Dimerix Limited (ASX: DXB) is a clinical-stage drug development company with our lead program DMX-200, currently in Phase II clinical trials for Chronic Kidney Disease (CKD).
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
